Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,041
datasets available to search
ShareScore release 0.9.0
Dataset results
1,041 results for “Targeted Therapy”
Associated code and data for "Multi-level computational modeling of anti-cancer dendritic cell vaccination utilized to select molecular targets for therapy optimization (doi: 10.3389/fcell.2021.74635)"
<p>This deposit contains the data, code, and analysis to reproduce the results in the manuscript - Lai X, Keller C, Santos-Rosales G, Schaft N, Dörrie J, Vera J. Multi-level computational modeling of anti-cancer dendritic cell vaccination utilized to select molecular targets for therapy optimization. Frontiers in Cell and Developmental Biolology. 2022; 9:746359; <a href="https://www.researchgate.net/publication/358461035_Multi-Level_Computational_Modeling_of_Anti-Cancer_Dendritic_Cell_Vaccination_Utilized_to_Select_Molecular_Targets_for_Therapy_Optimization">doi:10.3389/fcell.2021.746359</a>.</p> <p>If you have used the code for your research, please cite the original publication. Thank you very much.</p> <p> </p>
Fig. 3 in The Wolbachia endosymbiont of Brugia malayi has an active phosphoglycerate mutase: a candidate target for anti-filarial therapies
Fig. 3 Activity of recombinant wBm–iPGM. Conversion of 3-PG to 2-PG by MBP–wBm–iPGM (filled circle) is measured indirectly by a decrease in NADH concentration, determined spectrophotometrically at 340 nm. Consumption of NADH is directly proportional to PGM activity. A baseline control lacking wBm–iPGM (open circle) is shown
Fig. 1 in The Wolbachia endosymbiont of Brugia malayi has an active phosphoglycerate mutase: a candidate target for anti-filarial therapies
Fig. 1 Alignment of the deduced amino acid sequences of various iPGM enzymes. The sequence of iPGM from the Wolbachia endosymbiont of Brugia malayi (wBm; GenBank accession no. AAW70991) is aligned with the extensively studied and structurally characterized iPGM from Bacillus stearothermophilus (Bs; GenBank accession no. Q9X519; Jedrzejas et al. 2000a,b) and the characterized iPGM from Brugia malayi (Bm; GenBank accession no. AAQ97626; Zhang et al. 2004; Raverdy et al. 2007). Residues that are identical in at least two of the three sequences are shaded in black, while conserved amino acid changes are grey. The catalytic serine (@) and 13 other residues (*) involved in catalysis (Jedrzejas 2000) are conserved in all three enzymes. Alignment generated with ClustalW and displayed with BOXSHADE (www.ch.embnet.org/software/ BOX_form.html)
Fig. 2 in The Wolbachia endosymbiont of Brugia malayi has an active phosphoglycerate mutase: a candidate target for anti-filarial therapies
Fig. 2 Purification of MBP–wBm–iPGM expressed intracellularly in the yeast K. lactis. Fractions from the purification were analyzed by SDS-PAGE and the gel stained with Coomassie Blue. Lane 1 Protein Ladder (New England Biolabs), lane 2 K. lactis lysate, lane 3 supernatant of K. lactis lysate, lane 4 pellet of K. lactis lysate, lane 5 flow-through from amylose column, lane 6 column wash, lanes 7, 8, and 9, elution fractions. The arrowhead indicates the protein band corresponding to recombinant MBP–wBm–iPGM
'CellTrajectory' for cellular automata modelling of leukaemic stem cell dynamics in acute myeloid leukaemia: insights into predictive outcomes and targeted therapies
Open the record for dataset details and reuse information.
'Biosim' for cellular automata modelling of leukaemic stem cell dynamics in acute myeloid leukaemia: insights into predictive outcomes and targeted therapies
Open the record for dataset details and reuse information.
Replication Data for: Precision Oncology, Cell Signaling and Targeted Therapy: A Holistic Approach to Molecular Cancer Therapeutics
<p>In recent decades, there has been a deluge in the large-scale production of anticancer agents, primarily due to advances in genomic technologies enabling precise targeting of oncogenic pathways involved in disease progression. This initiated a paradigm shift in cancer research and therapeutics based on the ability to study molecular changes throughout the genome. It provided a unique opportunity in the field of translational cancer research and have led to the concept of precision medicine in cancer therapy, raising hopes of developing better diagnostic and therapeutic means for the management of cancer. The purpose of this article is to briefly review the tools and techniques involved in precision oncology research and their applications in the field of cancer treatment. </p>
Nuclear excitation functions for medical isotope production: targeted radionuclide therapy via nat Ir(d, x)193mPt
<p><sup>193m</sup>Pt is a medically valuable Auger-emitting radionuclide, believed to have therapeutic potential, particularly when labeled to the chemotherapeutic drug cisplatin. One challenge to broader explorations of its clinical potential is the need for production routes with high specific activity. As part of a larger campaign to address gaps in reaction data for emerging medical radionuclides, this work seeks to characterize the <sup>nat</sup>Ir(d,x) reactions as a potential production pathway for <sup>193m</sup>Pt. A stacked target irradiation, consisting of natural iridium, iron, nickel, and copper foils, was performed using a 33 MeV deuteron beam at the Lawrence Berkeley National Laboratory 88-Inch Cyclotron. This measurement, along with previous experimental data, suggests an energy window between 11 to 18 MeV to maximize the production and radiopurity of <sup>193m</sup>Pt. This experiment has yielded cross sections for 42 reaction channels of deuteron-induced reactions from threshold to 30 MeV, including the first experimental results of <sup>nat</sup>Ir(d,x)<sup>188m1+g,190m1+g</sup>Ir (cumulative), <sup>nat</sup>Ni(d,x)<sup>56,57,58m,58g</sup>Co (independent), <sup>nat</sup>Ni(d,x)<sup>53</sup>Fe (cumulative), and <sup>nat</sup>Fe(d,x)<sup>48 V, 51 Cr</sup>(cumulative). The results were compared with literature data, the TENDL-2019 database, and default theoretical calculations from the TALYS-1.9, CoH-3.5.3, EMPIRE-3.2.3, and ALICE-2017 reaction modeling codes. This work presents another example of the lack of predictive capabilities for this set of modern nuclear-reaction modeling codes, and highlights unsatisfactory modeling in the A ≈ 190 mass region, which proved particularly difficult to model using CoH-3.5.3. Finally, this measurement has revealed weaknesses with the current evaluation of the <sup>nat</sup>Cu(d,x)<sup>63</sup>Zn deuteron monitor reaction.</p>
THOR progress presentation 2022: Targeting Smooth Muscle Cells for Atherosclerosis Therapy
<p>This is a recorded talk with head of the THOR project - Jacob Fog Bentzon, where he presents the latest project progress.</p> <p>The talk was given at one of ODIN's (the Open Discovery Innovation Network) Knowledge Sharing Events in May 2022.</p>
Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance
<p><span>Resistance to targeted therapy remains a major clinical challenge in melanoma patients. To uncover resistance mechanisms, we performed single cell RNA sequencing of fine needle aspirates from resistant and responding tumors from melanoma patients before and during BRAFi/MEKi treatment. Among the genes most differentially expressed between malignant cells from resistant vs. responding tumors was POSTN encoding the secreted factor periostin. POSTN was predicted to predominantly signal to a macrophage population associated with targeted therapy resistance (TTR). Accordingly, tumors from patients with fast disease progression after targeted therapy exhibited high POSTN expression levels as well as high numbers of TTR macrophages, and POSTN was able to polarize macrophages towards a TTR phenotype. In a mouse model in vivo, POSTN expression protected melanoma from targeted therapy, which was associated with a phenotype change of intratumroal macrophages. Finally, polarized TTR macrophages protected melanoma cells from MEKi-induced killing through CD44 receptor expression on melanoma cells. Thus, interfering with the protective activity of TTR macrophages might represent a strategy to overcome resistance to targeted therapy in melanoma.</span></p>
Matrix stiffness influences response to chemo and targeted therapy in brain metastatic breast cancer cells
Open the record for dataset details and reuse information.
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
ClinicalTrials.gov study NCT01709578. IPD Sharing: Not stated. Countries: 30. Publications: 10.
Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
ClinicalTrials.gov study NCT02286843. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (
ClinicalTrials.gov study NCT02677922. IPD Sharing: Not stated. Countries: 14. Publications: 4.
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
ClinicalTrials.gov study NCT03085719. IPD Sharing: NO. Countries: 1. Publications: 0.
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
ClinicalTrials.gov study NCT04616547. IPD Sharing: YES. Countries: 1. Publications: 1.
Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome
ClinicalTrials.gov study NCT02670525. IPD Sharing: NO. Countries: 1. Publications: 1.
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
ClinicalTrials.gov study NCT02947685. IPD Sharing: NO. Countries: 8. Publications: 38.
Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery
ClinicalTrials.gov study NCT04291508. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
ClinicalTrials.gov study NCT02457598. IPD Sharing: NO. Countries: 3. Publications: 6.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.